What We Do

The Medicines Patent Pool (MPP) negotiates with patent holders for licences on HIV, hepatitis C and tuberculosis medicines. These licences permit multiple manufacturers to produce and distribute generic versions of patented medicines in developing countries. The licences also provide the freedom to develop new treatments such as fixed-dose combinations – single pills composed of several medicines – and special formulations for children. Competition between quality-assured generic pharmaceutical companies helps bring prices down and accelerates access to new treatments in developing countries.

Our Work
How the MPP contributes to international targets to end HIV, viral hepatitis and tuberculosis.
Licence Overview
The MPP works closely with industry – patent holders, generic manufacturers and product developers – to increase access to medicines.
Other Partnerships
The MPP has signed formal memoranda of understanding, and other agreements, with various parties. Information on these agreements is provided below.
Expression of Interest
Details on the criteria and process for applying for an MPP Expression of Interest (EOI) to sublicense a treatment for generic manufacture.
Understanding the potential use of current and pipeline treatments enables the MPP to plan its work with industry, and to guide its manufacturing partners and others on strategies and policies.
Target Medicines
The MPP works with the World Health Organization and other public health experts to prioritise products for licensing.
This website uses cookies to ensure you get the best experience on our website. Learn More